Shares in Verve Therapeutics ( VERV -0.54%) soared 80.5% this week on the news of an agreement for Eli Lilly ( LLY -2.54%) to ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Eli Lilly has announced its intention to acquire Verve Therapeutics, a biotechnology company specializing in gene-editing ...

Verve Therapeutics, Inc. (NASDAQ:VERV) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Eli Lilly and ...

Fintel reports that on June 18, 2025, LifeSci Capital downgraded their outlook for Verve Therapeutics (NasdaqGS:VERV) from ...

Fintel reports that on June 18, 2025, Jefferies downgraded their outlook for Verve Therapeutics (NasdaqGS:VERV) from Buy to ...

Verve Therapeutics remains an early-stage biotech, making the rally purely acquisition-driven, not based on fundamentals.

HealthDay News — Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives Lilly a potential new treatment for heart disease, The Wall ...

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a ...

Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising ...

Shares in Verve Therapeutics (NASDAQ: VERV) soared 80.5% this week on the news of an agreement for Eli Lilly (NYSE: LLY) to acquire Verve. Given that PCSK9 binds to low-density lipoprotein (LDL ...

Shares in Verve Therapeutics (VERV-0.49%) soared 80.5% this week on the news of an agreement for Eli Lilly (LLY-2.33%) to acquire Verve. The deal centers on an exciting cardiovascular health ...